AETHLON MEDICAL, INC. Accretion Expense
AETHLON MEDICAL, INC. (AEMD) reported Accretion Expense of $209.74 thousand for the 9-month period ending 2024-12-31, per its 10-Q filed 2025-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2025-02-12
- AETHLON MEDICAL, INC. accretion expense for the quarter ending 2019-06-30 was $661.00.
- AETHLON MEDICAL, INC. accretion expense for the quarter ending 2018-06-30 was $0.00.
| Period end | Accretion Expense 3 month | Accretion Expense 9 month |
|---|---|---|
| 2024-12-31 | $209.74K 10-Q · filed 2025-02-12 | |
| 2023-12-31 | $1.36K 10-Q · filed 2025-02-12 | |
| 2019-06-30 | $661.00 10-Q · filed 2019-08-14 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| Vivos Therapeutics, Inc. (VVOS) | United States | $0.003B | -0.26 |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |